Skip to main content

Table 1 Inclusion and exclusion criteria

From: Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension

Inclusion criteria Exclusion criteria
Patients aged ≥35 years Use of NPH or regular insulin, pioglitazone, GLP-1 receptor agonist, DPP-4 inhibitor or acarbose
History of DM and mild hypertension (blood pressure <160/100 mmHg) no longer than 15 years Intolerance to metformin
Body mass index <35 kg/m2 Use of three or more anti-hypertensive drugs, which characterizes resistant hypertension
Glycated hemoglobin (HbA1c) between 7.0 and 10.5 % Smoking within the previous 6 months
  Pregnancy or breastfeeding
  Creatinine clearance <45 mL/min (MDRD)
  Serum alanine aminotransferase or aspartate aminotransferase level of more than three times the upper limit of the normal range
  Subjects with ischemic heart disease, cerebrovascular disease, other atherosclerotic disease, cancer, or heart failure in functional classes II, III and IV
  Treadmill stress test with typical chest pain or with ST segment depression ≥1 mm, or with a horizontal or descending trace on the electrocardiogram for a duration of 0.08 s after the J point
  Presence of coronary heart disease diagnosed by treadmill stress test, myocardial scintigraphy or coronary angiography
  Inability to give informed consent